Provided by Tiger Trade Technology Pte. Ltd.

Larimar Therapeutics, Inc.

2.96
-0.1000-3.27%
Post-market: 2.960.00000.00%16:10 EDT
Volume:834.43K
Turnover:2.48M
Market Cap:307.84M
PE:-1.54
High:3.11
Open:3.11
Low:2.92
Close:3.06
52wk High:6.42
52wk Low:2.72
Shares:104.00M
Float Shares:57.54M
Volume Ratio:0.51
T/O Rate:1.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9258
EPS(LYR):-2.2711
ROE:-139.63%
ROA:-70.96%
PB:2.42
PE(LYR):-1.30

Loading ...

Larimar Therapeutics President, COO John B. Harlow Jr. Files Initial Beneficial Ownership Statement

Reuters
·
Yesterday

Larimar Therapeutics appoints John Harlow as COO

TIPRANKS
·
Sep 30

Larimar Therapeutics Names John Harlow President and COO

Reuters
·
Sep 30

Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer

THOMSON REUTERS
·
Sep 30

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neogen (NEOG), Larimar Therapeutics (LRMR) and Sagimet Biosciences, Inc. Class A (SGMT)

TIPRANKS
·
Sep 28

U.S. Research Roundup-ACV Auctions, Crown Castle, Lennox International

Reuters
·
Sep 14

Century Therapeutics Appoints Joseph Truitt to Board of Directors

THOMSON REUTERS
·
Sep 10

Larimar Therapeutics Q2 EPS USD -0.3

THOMSON REUTERS
·
Aug 04

Larimar Therapeutics - Projects Cash Runway into Q3 2027

THOMSON REUTERS
·
Aug 04

Larimar Therapeutics Q2 Net Income USD -32.782 Million

THOMSON REUTERS
·
Aug 04

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

THOMSON REUTERS
·
Aug 04

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
Jul 14

Larimar Therapeutics director buys $167K in common stock

TIPRANKS
·
Jul 09

Larimar Therapeutics Director Thomas Edward Hamilton Acquires USD 166,890 of Common Shares

Reuters
·
Jul 09

Adobe, Larimar, Palantir, Chevron, eXp Trending With Analysts

TIPRANKS
·
Jul 04

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 30

Larimar Therapeutics selloff a buying opportunity, says Citi

TIPRANKS
·
Jun 30

Nomlabofusp Progress and Durable Efficacy Support Buy Rating on LRMR with Unchanged $25 Price Target

TIPRANKS
·
Jun 30

Larimar stumbles on safety news even as BLA submission kicks off

TIPRANKS
·
Jun 29

Larimar Tumbles as Safety Concerns Resurface in Rare Disease Drug Study Update

Reuters
·
Jun 29